GlassScriptPhysician profile
Russell Coryell
NPI 1366811721
$4,872.98
in general payments reported to CMS, 2019-2025
28 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,059 · 2022: $794 · 2023: $903 · 2024: $1,083 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,020.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $678.48 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $635.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Mylan Specialty L.P. | $513.13 | 2021-2024 | Yupelri |
| Abbvie INC. | $468.05 | 2021-2025 | |
| Glaxosmithkline, LLC. | $440.47 | 2021-2024 | Trelegy Ellipta, Arexvy, Pediarix |
| Insulet Corporation | $423.72 | 2023-2025 | Omnipod |
| Novo Nordisk INC | $225.70 | 2021-2025 | Ozempic, Wegovy |
| Medtronic, INC. | $198.50 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.44 | 2021-2024 | Spiriva Respimat |
| Abiomed | $167.65 | 2024-2025 | Impella |
| Viatris Specialty LLC | $164.04 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $115.77 | 2022-2025 | Gvoke Hypopen |
| Abbott Laboratories | $112.00 | 2022-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $88.98 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $80.75 | 2021-2023 | Ajovy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $71.71 | 2021 | |
| Axsome Therapeutics, INC. | $60.88 | 2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $59.64 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $38.88 | 2021-2024 | |
| Lundbeck LLC | $25.74 | 2024 | Rexulti |
| Radius Health, INC. | $21.39 | 2021 | |
| Beta Bionics, INC. | $19.16 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Exact Sciences Corporation | $16.10 | 2025 | The Cologuard Plus Collection Kit |
| Becton, Dickinson and Company | $15.94 | 2023 | Bd Onclarity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.25 | 2025 | Caplyta |
| Eisai INC. | $14.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.37 | 2021 | |
| Organon LLC | $2.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Coryell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.